02487nas a2200253   4500008003900000245019500039210006900234260000800303300000700311490000700318520166700325653004401992100001102036700001802047700001702065700001402082700001502096700001302111700001602124700001702140700001702157700001402174856004502188       2022                          d00aRelationship between allergic sensitisation-associated single-nucleotide polymorphisms and allergic transfusion reactions and febrile non-haemolytic transfusion reactions in paediatric cases0 aRelationship between allergic sensitisationassociated singlenucl  cMar  a940 v203 aBackground: Allergic transfusion reactions (ATR) and febrile non-haemolytic transfusion reactions (FNHTR) are common transfusion-related adverse reactions; however, their pathogenesis remains unclear and it is difficult to predict their occurrence. Single-nucleotide polymorphisms (SNP) are related to the onset of various diseases and therapy-related adverse events; therefore, identification of SNP related to transfusion-related adverse reactions may help to elucidate the underlying mechanism and predict the onset of these reactions.

Materials and methods: We retrospectively analysed the association between the onset of ATR or FNHTR and 22 allergic sensitisation-related SNP in 219 children (aged ≤20 years) who had haematological and oncological diseases and who had received transfusions of platelets and/or red blood cell concentrates.

Results: Among the 219 children, 105 had developed an ATR and/or FNHTR at least once. The patients who developed ATR frequently had a risk allele in rs6473223, while the patients who developed FNHTR frequently had a risk allele in rs10893845. Furthermore, patients who developed ATR accompanied by febrile symptoms also frequently had a risk allele in rs10893845, similar to patients who developed FNHTR.

Discussion: The results suggested that allergic sensitisation is associated with the onset of ATR and/or FNHTR in some patients. Although further prospective evaluation is necessary, analysis of these SNP might help to provide safer transfusion therapy by predicting patients at higher risk of transfusion-related adverse reactions and further clarifying the pathogenic mechanism underlying such reactions.10aATR, children, FNHTR, polymorphism, SNP1 aIde, Y1 aYanagisawa, R1 aKobayashi, J1 aKomori, K1 aMatsuda, K1 aAmano, Y1 aNakazawa, Y1 aTakeshita, T1 aSakashita, K1 aTozuka, M  uhttp://613633.bywedr.asia/reference/4998